Pharmacogenomic Testing for the Lithuanian Depression Patients

ABSTRACT PcA1-3

ALGIRDAS UTKUS
Dean of the Faculty of Medicine, Chairman of Department of Human and Medical Genetics, Vilnius University, Vilnius, Lithuania

EDGARAS DLUGAUSKAS
Vilnius University Hospital Santaros Klinikos

EVELINA DAGYTĖ
Vilnius University Hospital Santaros Klinikos

ABSTRACT DESCRIPTION

Major depressive disorder is among the leading causes of disease burden and disability, as well as a major public health concern worldwide. Clinical Pharmacogenomics attempts to link identifiable genetic variants to the prediction of drug response. A group of 47 Lithuanian patients with Moderate depressive episode/Recurrent depressive disorder, current episode moderate according to ICD-10 or patients with Severe depressive episode without psychotic symptoms/Recurrent depressive disorder, current episode severe without psychotic symptoms have been included in the study. Healthy with no depression symptoms according to BDI individuals have been included as a control group. Genetic testing using multiple ligation probe amplification and sequencing techniques have been performed for detecting alleles of CYP2D2, CYP2D19, CYP1A2, HTR2A, SLC6A4 pharmacogenes.